Question 1

What is the difference between somatropin and HGH?

Accepted Answer

One is the hormone, the other is the name on a carton. HGH is human growth hormone, which a body makes for itself. Somatropin is the manufactured copy, and recombinant human growth hormone — rhGH in the trial reports — is that same copy under a third name. The reference entry for the oldest version makes the naming habit visible, because somatrem is described only against the closely related recombinant human growth hormone, somatropin, rather than by anything of its own. A registry of 83,803 patients calls its exposure rhGH throughout, covering children treated with recombinant human growth hormone (rhGH) in real-world settings. So somatropin, rhGH and HGH are not three grades of one thing. They are one molecule wearing a pharmacy name, a laboratory name and a street name, and only the first of the three ever appears on an approved carton.

Question 2

What does 191aa mean on an HGH label?

Accepted Answer

Nothing a buyer can check, and that is the whole of the honest answer. Among these sources, versions are told apart by name and by how long they last, never by a count of amino acids. A 2021 approval summary describes lonapegsomatropin as a long-acting prodrug of somatropin (human growth hormone), and the older somatrem entry marks itself out only as closely related to somatropin. The FDA enforcement listings do not use the figure either. What a documented carton prints is a form and a strength, such as a 5 mg (15 IU) 1-count bottle, with a firm and an address beside it. A number stamped on an unlabelled vial is therefore a claim made by whoever printed it, and nothing among these sources tests such a claim. On an approved injection the identity question is settled by the filing behind it rather than by a figure on the box, and that is the real difference the phrase is reaching for.

Question 3

Is IGF-1 stronger than HGH?

Accepted Answer

The question treats the two as rivals. In this evidence they are a cause and its readout. IGF-1 is insulin-like growth factor 1, the blood signal that climbs when growth hormone acts, and the trials track it to confirm the injection is working and to decide how much of it to give. Across the six-year extension, mean values of weekly average IGF-1 remained within 0-2 SDS throughout the trial. In an adult study of twenty people, doses were titrated over 3 months to maintain IGF-1 levels within ± 2 SD, and when the authors then set two schedules against each other they did it with IGF-1 levels matched between regimens. Read what that makes IGF-1 in this record: a dial the clinicians held still so that something else could be compared. Nothing among these sources injects IGF-1 or measures an outcome from doing so. Injected IGF-1 is a separate compound with a record of its own, set out at the IGF-1 safety page.

Question 4

Is IGF-1 LR3 better than HGH for muscle growth?

Accepted Answer

No comparison among these sources puts the two side by side, and they sit at different points on the same chain. IGF-1 LR3 is a modified form of insulin-like growth factor 1, which is the signal growth hormone produces downstream; growth hormone itself is the upstream instruction. Nothing in this record gave either form of IGF-1 to anybody. What it does hold on the muscle question belongs to growth hormone and to an illness, since somatropin derived from mammalian cells is the only US FDA-approved treatment indicated to increase lean body mass, bodyweight and physical endurance in HIV-associated wasting. That is one approved use inside one disease, measured against placebo in patients who had been losing mass. Setting an unmeasured compound against a figure like that is not a comparison, because only one side of it carries a number, which is not the same as the two coming out level. What has and has not been given to people as IGF-1 is at the IGF-1 dosage page.

Question 5

What is the difference between a growth-hormone secretagogue and HGH?

Accepted Answer

One supplies the hormone; the other asks a gland to release more of its own. Everything measured in this record is the first kind — manufactured growth hormone, injected under the skin, into children and adults whose own supply was short. A 2021 approval summary puts the mechanics plainly, recording that lonapegsomatropin is administered as a once-weekly subcutaneous injection and that the sustained release of somatropin from it eliminates the need for daily somatropin injections. The second kind never appears at all. No study among the research behind this page gave a releasing compound to anybody or measured an outcome from one, so what this page can state is a difference of mechanism and of regulatory standing rather than a difference of effect. Sermorelin, CJC-1295 and ipamorelin each carry evidence of their own. The sermorelin side of the question is laid out at the Sermorelin comparison page, and CJC-1295's at the CJC-1295 comparison page.

Question 6

What is the difference between HGH Fragment 176-191 and tesamorelin?

Accepted Answer

The honest first move is to say that neither of them is growth hormone, and that neither appears among these sources. Both names describe something other than the whole hormone — one a fragment of it, the other a compound named for releasing it — so a result belonging to growth hormone does not carry across to either. What this record covers is the hormone itself and its approved versions, among them lonapegsomatropin, which received its first approval in August 2021 in the USA for pediatric patients at least 1 year of age. Three different molecules cannot borrow one another's evidence, however similar the names look on a price list. So the difference between those two belongs to their own pages rather than to this one. What has been given to people under the fragment's other name sits at the AOD-9604 dosage page, and tesamorelin carries a page of its own.

Question 7

Daily or weekly: which schedule has more evidence behind it?

Accepted Answer

Three randomised trials put the two schedules against each other, and daily somatropin was the comparator in all three, which says which of the two the field already treated as settled. The first was a randomized, open-label, active-controlled, 52-week Phase 3 trial, and it enrolled and dosed 161 treatment-naïve, prepubertal patients with GHD. The second ran as a 12-month, open-label, randomized, active-controlled, parallel-group, phase 3 study in 228 prepubertal children. The third was much smaller, with 44 prepubertal Japanese children with GHD. Two of the three were built to show noninferiority, meaning the weekly version only had to avoid coming out meaningfully worse: one of them declared its result against a prespecified noninferiority margin (-1.8 cm/year). What the figures came out at belongs to the HGH results page. What belongs on this page is the design — three trials, one of them small, all of them open-label, and all of them asking about convenience rather than about whether the hormone does anything.

Question 8

How do the long-acting versions differ from one another?

Accepted Answer

Three weekly versions appear in this record and they are built in three different ways. The first is a carrier system: lonapegsomatropin is a long-acting prodrug of somatropin, which means it holds the ordinary hormone and lets it go slowly, and the carrier is polyethylene glycol, which a lactation entry notes is not excreted into breastmilk. The second is a modified protein, since somatrogon is a long-acting recombinant human growth hormone (rhGH) in development for once-weekly treatment of children with growth hormone deficiency. The third is somapacitan, a long-acting GH derivative, and it is the only one of the three with a published adult record. Those are three engineering answers to one problem. Every published comparison sets each of them against daily somatropin rather than against the other two, and no trial among these sources has put two weekly versions into the same study.

Question 9

Is one approved version interchangeable with another?

Accepted Answer

This is the only comparison in the field a regulator has ruled on, and the ruling is careful rather than clean. An approved copy is one filed for market approval by a second firm, after the patent on the first has run out. Copies of recombinant somatropin have gained market authorisation in the EU. Getting there took proof, since similarity in terms of quality, safety and efficacy to a reference product was demonstrated. Swapping one for another is then a question of its own. The same 2011 review says there are points to consider when switching from the innovator product to a biosimilar, or from one biosimilar to another, and it lists naming, labelling and substitution among the things still being argued over. So two approved copies of one hormone are held to be alike, and they are not declared the same thing. If the bar sits there between two regulated versions, it is worth asking where it leaves a vial with no label on it.

Question 10

Is HGH ever given alongside another compound?

Accepted Answer

Once in the published record, and the pairing is not the kind the question usually means. In short bowel syndrome, recipients of subcutaneous somatropin alone or somatropin plus oral glutamine had significantly greater mean reductions from baseline in weekly total IPN volume than recipients of placebo plus glutamine. Glutamine sat in both arms, so that trial weighs growth hormone added to glutamine against glutamine on its own, rather than testing a combination against either part. A 2014 review names a second compound approved for the same condition, the glucagon-like peptide 2 analog teduglutide, but names it alongside growth hormone rather than in combination with it. Nothing among these sources gives growth hormone with a releasing peptide, with IGF-1, or with anything sold as a stack. A pairing that has been administered and a pairing that has been measured are different things, and this record holds one example of the first.

Question 11

What does HGH have that the compounds beside it do not?

Accepted Answer

Four things, and none of them is an effect size. The first is a named indication, since lonapegsomatropin was approved for growth failure due to inadequate secretion of endogenous growth hormone. The second is scale: the full KIGS cohort (N = 83 803 [58% male]) was followed across six growth diagnoses. The third is duration, because an open-label extension ran for years and reported that growth was maintained throughout pubertal development and the dose remained stable throughout the trial. The fourth is an enforcement record, which is a form of evidence people forget to count. Eight recalls of regulated somatropin sit between 2012 and 2021, one of them filed for Lack of Assurance of Sterility. A compound holding none of those four is not thereby worse than growth hormone. It is unmeasured on all four axes rather than measured and found wanting, and those are different positions to argue from.

Question 12

Which comparison questions have no published answer?

Accepted Answer

Several, and naming them is more useful than improvising around them. Testosterone and anabolic steroids appear in none of these sources, so this page holds no comparison with either; the approval boundary that question really turns on is covered at the HGH sourcing page. HCG does not appear in them either, and it carries a page of its own. What these sources do cover is named precisely: idiopathic GH deficiency (IGHD; 46.9%), organic GHD (10.0%), small for gestational age (SGA; 9.5%), Turner syndrome (TS; 9.2%), idiopathic short stature (ISS; 8.2%), and others (16.2%) in children, plus two illnesses in adults. Nothing outside that list has been set beside growth hormone by anybody we cite. One further gap sits underneath the rest: no study we could find has compared an approved injection with material bought outside a pharmacy, so the comparison most readers are actually making — this vial against that one — has not been performed by anybody who published a result.

Question 13

Why does this page not pick a winner?

Accepted Answer

Because the comparison that exists and the comparison people want are not the same thing. What exists is one schedule set against another, in children with a diagnosis, with daily somatropin as the yardstick every time. The gaps came out small. One trial reported its weekly arm only as noninferior to the daily one, and a second concluded that the two were comparable. What people want is one compound placed above another, for a use no approval covers, measured in bodies nobody enrolled. Ranking the first set would say nothing honest about the second. A narrower statement is worth making instead. Among these sources, growth hormone is the only compound named on this page that holds an approved use, a large registry and a published recall history. That is a statement about how much is known, rather than about how well anything works.

Trial	Who was enrolled	Length	Design
First	161 treatment-naïve, prepubertal patients with GHD	52 weeks	Phase 3, active-controlled
Second	228 prepubertal children	12 months	Phase 3, active-controlled, parallel-group
Third	44 prepubertal Japanese children with GHD	Not stated here	Much smaller

HGH comparisons and stacks